LCTX vs DNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DNA Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ginkgo Bioworks Holdings, Inc. (DNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | DNA Revenue | LCTX Op. Margin | DNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -837.9% | N/A | LCTX |
| FY2019 | $0M | $50M | -1106.0% | -132.1% | DNA |
| FY2020 | $0M | $80M | -1448.4% | -178.8% | DNA |
| FY2021 | $0M | $310M | -1133.6% | -582.6% | DNA |
| FY2022 | $10M | $480M | -153.2% | -462.4% | LCTX |
| FY2023 | $10M | $250M | -276.5% | -343.8% | LCTX |
| FY2024 | $10M | $230M | -226.1% | -246.5% | LCTX |
| FY2025 | $10M | $170M | -251.6% | -185.3% | DNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | DNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $212.1M | $547.1M | Larger Scale | DNA |
| Trailing P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | -5.7% | Higher Growth | DNA |
| Operating Margin (TTM) Profitability | -280.3% | -202.5% | Higher Margin | DNA |
| Net Profit Margin Profitability | 16.2% | -192.0% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -58.2% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 4% ($1โ$2) | 22% ($5โ$18) | Stronger Trend | DNA |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 79% Vol | 3.12ฮฒ ยท 149% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 58.9 / 100 (HOLD) | 58.4 / 100 (HOLD) | Higher Composite | LCTX |